MedAvail Holdings マネジメント

マネジメント基準チェック /14

MedAvail Holdingsの CEO はMark Doerrで、 Jan2022年に任命され、の在任期間は 2.08年です。の年間総報酬は$ 2.52Mで、 16.8%給与と83.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.23%を直接所有しており、その価値は$ 6.79K 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と2.7年です。

主要情報

Mark Doerr

最高経営責任者

US$2.5m

報酬総額

CEO給与比率	16.8%
CEO在任期間	2.1yrs
CEOの所有権	0.2%
経営陣の平均在職期間	2.4yrs
取締役会の平均在任期間	2.7yrs

経営陣の近況

Recent updates

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

Aug 17

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

Feb 20

CEO報酬分析

MedAvail Holdings の収益と比較して、Mark Doerr の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$55m
Dec 31 2022	US$3m	US$424k	-US$48m

報酬と市場: Markの総報酬 ($USD 2.52M ) は、 US市場 ($USD 652.28K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Mark Doerr (53 yo)

2.1yrs

在職期間

US$2,524,419

報酬

Mr. Mark Doerr, RPh serves as Chief Executive Officer, President and Director at MedAvail Holdings, Inc since January 10, 2022. He serves as the Chief Executive Officer of eRx Network, LLC since March 28,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Doerr	CEO, President & Director	2.1yrs	US$2.52m	0.23% $ 6.8k
Ramona Seabaugh	CFO, Treasurer & Secretary	2.4yrs	US$537.22k	0.076% $ 2.2k
Emilia Keric	Senior VP & General Counsel	less than a year	データなし	データなし
Joan O'Rourke	President of SpotRx	2.8yrs	データなし	データなし
Brian Schlerf	Corporate Controller	3.1yrs	データなし	データなし

2.4yrs

平均在職期間

経験豊富な経営陣: MDVLの経営陣は経験豊富であると考えられます ( 2.4年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mark Doerr	CEO, President & Director	2.1yrs	US$2.52m	0.23% $ 6.8k
Robert Faulkner	Chairman of the Board	3.3yrs	データなし	0.12% $ 3.6k
Laurie McGraw	Independent Director	2.1yrs	US$217.96k	0% $ 0
Michael Kramer	Independent Director	3.3yrs	US$187.00k	0% $ 0
Glen Stettin	Independent Director	3.3yrs	US$170.00k	0% $ 0
Paul Johnson	Independent Director	2.1yrs	US$224.96k	0% $ 0

2.7yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: MDVLの取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

MedAvail Holdings マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

MedAvail Holdings, Inc. Announces Board of Directors Resignations

High number of new and inexperienced directors

High number of new and inexperienced directors

Medavail Holdings, Inc. Announces Executive Resignations

High number of new and inexperienced directors

MedAvail Holdings, Inc., Annual General Meeting, Jun 14, 2022

Recent updates

MedAvail Holdings, Inc.(OTCPK:MDVL.Q) dropped from S&P TMI Index

MedAvail Holdings, Inc.(OTCPK:MDVL.Q) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of MedAvail Holdings

MedAvail Holdings, Inc. Filed for Bankruptcy

MedAvail Holdings, Inc. Announces Board of Directors Resignations

MedAvail Holdings, Inc. announced delayed 10-Q filing

Slammed 31% MedAvail Holdings, Inc. (NASDAQ:MDVL) Screens Well Here But There Might Be A Catch

High number of new and inexperienced directors

MedAvail Announces 1-for-50 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

MedAvail Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

MedAvail Holdings, Inc. announced delayed 10-Q filing

Full year 2022 earnings: EPS exceeds analyst expectations

High number of new and inexperienced directors

Medavail Holdings, Inc. Announces Executive Resignations

German Dobson CVS, L.L.C., Garfield Beach CVS, L.L.C., Holiday CVS, L.L.C., Longs Drug Stores California, Inc. and Woodward Detroit CVS, L.L.C. entered into the asset purchase and sale agreement to acquire Pharmacy Assets of MedAvail Holdings, Inc. for $4.4 million.

Medavail Holdings, Inc. Initiates Reduction in Force

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MedAvail Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

MedAvail Holdings Receives A Letter from Nasdaq Regarding Minimum Bid Price Requirement

MedAvail Holdings, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 31%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

MedAvail Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

MedAvail Holdings: More Stock Dilution Seems Inevitable And I'm Bearish

MedAvail Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

MedAvail Holdings, Inc.(NasdaqCM:MDVL) dropped from Russell 2000 Growth Index

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

MedAvail Holdings, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$5.00

Less than half of directors are independent

Consensus estimates of losses per share improve by 22%

Price target increased to US$8.00

MedAvail Holdings, Inc announced that it expects to receive $50.04375 million in funding

Medavail Holdings, Inc Strengthens Leadership Team

MedAvail Holdings, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Price target decreased to US$7.50

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.74 loss in 3Q 2020)

Consensus revenue estimates fall to US$21.1m

Some Analysts Just Cut Their MedAvail Holdings, Inc (NASDAQ:MDVL) Estimates

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$4.11 loss in 2Q 2020)

Medavail Holdings, Inc Revises Revenue Guidance for the Full Year 2021

Calculating The Intrinsic Value Of MedAvail Holdings, Inc (NASDAQ:MDVL)

MedAvail Holdings, Inc Narrows Revenue Guidance for the Full Year of Fiscal 2021

Full year 2020 earnings released: US$0.84 loss per share (vs US$16.85 loss in FY 2019)

MedAvail Holdings, Inc to Report Q4, 2020 Results on Mar 30, 2021

Is There An Opportunity With MedAvail Holdings, Inc's (NASDAQ:MDVL) 32% Undervaluation?

MedAvail’s SpotRx Pharmacy and Cigna Medical Group Partner to Help Improve Medication Access in Phoenix

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14